Pharma Giant’s new drug shows promise in protecting kidneys for diabetes patients
Pharma Giant has announced a significant breakthrough in kidney protection for patients with type 1 diabetes and chronic kidney disease. Meanwhile, the company prepares for a major restructuring and welcomes a new CFO with extensive international experience.
In a Phase 3 trial, finerenone, a drug developed by Pharma Giant, demonstrated a 25% reduction in urinary albumin-to-creatinine ratio (UACR) compared to placebo. This result indicates a clinically relevant improvement in kidney protection, potentially slowing disease progression and reducing the risk of further kidney damage. The drug could soon emerge as a major treatment option for these patients.
The company also announced the appointment of Judith Hartmann as its new CFO. Hartmann, who will join the executive board on March 1, 2026, and take over as CFO on June 1, succeeds Wolfgang Nickl. With a robust background that includes roles at Sandbrook Capital, Engie, and Bertelsmann, Hartmann brings a wealth of experience to the position. She will face significant challenges, including portfolio restructuring and managing the legacy costs of glyphosate litigation. However, her international expertise is expected to provide clear financial direction, especially during the planned split of Pharma Giant into two independent companies.
Finerenone's promising results in kidney protection offer hope for patients with type 1 diabetes and chronic kidney disease. Meanwhile, Judith Hartmann's appointment as CFO signals a new era of leadership at Pharma Giant, with her extensive experience poised to navigate the company through significant changes.
